Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: A randomised controlled, four-arm, open-label, non-inferiority trial

The Lancet Infectious Diseases

Volumn 15, Issue 8, 2015, Pages 889-897

  Mir, Fatima ^a   Quadri, Farheen ^a   Mach, Ondrej ^b   Ahmed, Imran ^a   Bhatti, Zaid ^a   Khan, Asia ^a   Rehman, Najeeb Ur ^a   Durry, Elias ^c   Salama, Maha ^b   Oberste, Steven M ^d   Weldon, William C ^d   Sutter, Roland W ^b   Zaidi, Anita K M ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Polio Eradication Initiative WHO   (Pakistan)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATERNAL ANTIBODY; POLIOMYELITIS VACCINE; ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ARTICLE; BIRTH WEIGHT; CHILD DEATH; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COMMUNITY CARE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LOWEST INCOME GROUP; MALE; MULTICENTER STUDY; NEWBORN; OPEN STUDY; OUTCOME ASSESSMENT; PAKISTAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; POPULATION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; SEPSIS; SEROCONVERSION; SEROPREVALENCE; TREATMENT RESPONSE; CLINICAL TRIAL; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PROCEDURES;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; PAKISTAN; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL;

EID: 84937733636     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00093-6     Document Type: Article

References (41)

1. Robertson SE, Chan C, Kim-Farley R, Ward N Worldwide status of poliomyelitis in 1986, 1987 and 1988, and plans for its global eradication by the year 2000. World Health Stat Q 1990, 43:80-90.
2. Wild poliovirus 2009-14 WHO, (accessed Sept 16, 2014). http://www.polioeradication.org/Portals/0/Document/Data&Monitoring/Wild_poliovirus_list_2009_2014_29JUL.pdf.
3. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep 2001, 50:222-224. Centers for Disease Control and Prevention.
4. Wild poliovirus (WPV) case breakdown by country Global polio eradication initiative, (accessed Sept 16, 2014). http://www.polioeradication.org/dataandmonitoring/poliothisweek.aspx.
5. Boone J Taliban leader bans polio vaccinations in protest at drone strikes. The Guardian (London) June 26, 2012, (accessed Aug 26, 2014). http://www.theguardian.com/world/2012/jun/26/taliban-bans-polio-vaccinations.
6. Statement on the meeting of the International Health Regulations Emergency Committee concerning the international spread of wild poliovirus WHO, (accessed May 5, 2014). http://who.int/mediacentre/news/statements/2014/polio-20140505/en/.
7. Baicus A History of polio vaccination. World J Virol 2012, 1:108-114.
8. Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol Rec 2014, 89:73-92. WHO.
9. Halsey N, Galazka A The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bull World Health Organ 1985, 63:1151-1169.
10. Sabin AB Oral, live poliovirus vaccine for elimination of poliomyelitis. Arch Intern Med 1960, 106:5-9.
11. Salisbury D Immunisation policies and programmes in Europe. Biologicals 1994, 22:313-315.
12. Sutter RW, Kew OM, Cochi SL, Aylward RB Poliovirus vaccine-live. Vaccines 2013, 598-645. WB Saunders, London. 6th edn. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
13. WHO vaccine-preventable diseases: monitoring system. 2014 global summary WHO, (accessed May 21, 2015). http://apps.who.int/immunization_monitoring/globalsummary.
14. Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995, 754:289-299.
15. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. J Infect Dis 1997, 175(suppl 1):S215-S227.
16. el-Sayed N, el-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 2008, 359:1655-1665.
17. Progress toward poliomyelitis eradication-Afghanistan and Pakistan, 2009. MMWR Morb Mortal Wkly Rep 2010, 59:268-272. Centers for Disease Control and Prevention.
18. Deming MS, Jaiteh KO, Otten MW, et al. Epidemic poliomyelitis in The Gambia following the control of poliomyelitis as an endemic disease. II. Clinical efficacy of trivalent oral polio vaccine. Am J Epidemiol 1992, 135:393-408.
19. Hale JH, Doraisingham M, Kanagaratnam K, Leong KW, Monteiro ES Large-scale use of Sabin type 2 attenuated poliovirus vaccine in Singapore during a type 1 poliomyelitis epidemic. Br Med J 1959, 1:1541-1549.
20. Ashkenazi A, Melnick JL Heterotypic antibody response after feeding of monovalent attenuated live poliovaccine. N Engl J Med 1962, 267:1228-1230.
21. Polio eradication & endgame strategic plan 2013-18 Global polio eradication initiative, (Oct 26, 2013). http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_US.pdf.
22. World Health Organization collaborative study group on oral poliovirus vaccine. J Infect Dis 1995, 171:1097-1106. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and The Gambia.
23. Parent du Chatelet I, Merchant AT, Fisher-Hoch S, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003, 21:1710-1718.
24. Isomura S, Mubina A, Dure-Samin A, et al. Virological and serological studies on poliomyelitis in Karachi, Pakistan. I. Outbreaks in 1990-91. Acta Paediatr Jpn 1993, 35:382-386.
25. Linder N, Handsher R, Fruman O, et al. Effect of maternal immunization with oral poliovirus vaccine on neonatal immunity. Pediatr Infect Dis J 1994, 13:959-962.
26. Yin-Murphy M, Tan KL, Lim GN, Quek JH, Ishak B, Phoon MC Poliovirus neutralising antibody in infants and cord blood. Ann Acad Med Singapore 1993, 22:281-285.
27. Deming MS, Linkins RW, Jaiteh KO, Hull HF The clinical efficacy of trivalent oral polio vaccine in The Gambia by season of vaccine administration. J Infect Dis 1997, 175(suppl 1):S254-S257.
28. Dowell SF Seasonal variation in host susceptibility and cycles of certain infectious diseases. Emerg Infect Dis 2001, 7:369-374.
29. Grassly NC, Jafari H, Bahl S, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis 2012, 205:1554-1561.
30. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, et al. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 1960, 173:1521-1526.
31. Feldman RA, Holguin AH, Gelfand HM Oral poliovirus vaccination in children: a study suggesting enterovirus interference. Pediatrics 1964, 33:526-533.
32. Maldonado YA, Pena-Cruz V, de la Luz Sanchez M, et al. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis 1997, 175:545-553.
33. Myaux JA, Unicomb L, Besser RE, et al. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J 1996, 15:204-209.
34. Posey DL, Linkins RW, Oliveria MJ, Monteiro D, Patriarca PA The effect of diarrhea on oral poliovirus vaccine failure in Brazil. J Infect Dis 1997, 175(suppl 1):S258-S263.
35. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013, 368:416-424.
36. Diez-Domingo J, Cantarino MV, Torrenti JM, et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J 2010, 29:148-152.
37. Mallet E, Belohradsky BH, Lagos R, et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 2004, 22:1343-1357.
38. Herremans TM, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999, 162:5011-5018.
39. Contreras G, Dimock K, Furesz J, et al. Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals 1992, 20:15-26.
40. John TJ Anomalous observations on IPV and OPV vaccination. Dev Biol (Basel) 2001, 105:197-208.
41. Pavlov DN, Van Zyl WB, Van Heerden J, Grabow WO, Ehlers MM Prevalence of vaccine-derived polioviruses in sewage and river water in South Africa. Water Res 2005, 39:3309-3319.